141 related articles for article (PubMed ID: 31616290)
1. The Trials and Tribulations of Structure Assisted Design of K
Shim H; Brown BM; Singh L; Singh V; Fettinger JC; Yarov-Yarovoy V; Wulff H
Front Pharmacol; 2019; 10():972. PubMed ID: 31616290
[TBL] [Abstract][Full Text] [Related]
2. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-
Brown BM; Shim H; Zhang M; Yarov-Yarovoy V; Wulff H
Mol Pharmacol; 2017 Oct; 92(4):469-480. PubMed ID: 28760780
[TBL] [Abstract][Full Text] [Related]
3. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
4. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Coleman N; Brown BM; Oliván-Viguera A; Singh V; Olmstead MM; Valero MS; Köhler R; Wulff H
Mol Pharmacol; 2014 Sep; 86(3):342-57. PubMed ID: 24958817
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
[TBL] [Abstract][Full Text] [Related]
8. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
9. Channelopathy of small- and intermediate-conductance Ca
Nam YW; Downey M; Rahman MA; Cui M; Zhang M
Acta Pharmacol Sin; 2023 Feb; 44(2):259-267. PubMed ID: 35715699
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the KCa3.1 channel-calmodulin interactions to the regulation of the KCa3.1 gating process.
Morales P; Garneau L; Klein H; Lavoie MF; Parent L; Sauvé R
J Gen Physiol; 2013 Jul; 142(1):37-60. PubMed ID: 23797421
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
12. SKA-31, an activator of endothelial Ca
Khaddaj-Mallat R; Mathew John C; Braun AP
Eur J Pharmacol; 2018 Jul; 831():60-67. PubMed ID: 29753043
[TBL] [Abstract][Full Text] [Related]
13. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Oliván-Viguera A; Valero MS; Coleman N; Brown BM; Laría C; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Wulff H; Badorrey R; Köhler R
Mol Pharmacol; 2015 Feb; 87(2):338-48. PubMed ID: 25468883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Targeting of KCa Channels to Improve Endothelial Function in the Spontaneously Hypertensive Rat.
Khaddaj Mallat R; Mathew John C; Mishra RC; Kendrick DJ; Braun AP
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315169
[TBL] [Abstract][Full Text] [Related]
15. Allosteric inhibitors targeting the calmodulin-PIP2 interface of SK4 K
Burg S; Shapiro S; Peretz A; Haimov E; Redko B; Yeheskel A; Simhaev L; Engel H; Raveh A; Ben-Bassat A; Murninkas M; Polak R; Haitin Y; Etzion Y; Attali B
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2202926119. PubMed ID: 35969786
[TBL] [Abstract][Full Text] [Related]
16. SKA-31, an activator of Ca
John CM; Khaddaj Mallat R; Mishra RC; George G; Singh V; Turnbull JD; Umeshappa CS; Kendrick DJ; Kim T; Fauzi FM; Visser F; Fedak PWM; Wulff H; Braun AP
Pharmacol Res; 2020 Jan; 151():104539. PubMed ID: 31707036
[TBL] [Abstract][Full Text] [Related]
17. K
Orfali R; AlFaiz A; Rahman MA; Lau L; Nam YW; Zhang M
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509419
[TBL] [Abstract][Full Text] [Related]
18. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
Wulff H; Köhler R
J Cardiovasc Pharmacol; 2013 Feb; 61(2):102-12. PubMed ID: 23107876
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels.
Mishra RC; Wulff H; Hill MA; Braun AP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):118-27. PubMed ID: 25815673
[TBL] [Abstract][Full Text] [Related]
20. Channelopathy-causing mutations in the S
Orfali R; Nam YW; Nguyen HM; Rahman MA; Yang G; Cui M; Wulff H; Zhang M
Cell Calcium; 2022 Mar; 102():102538. PubMed ID: 35030515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
